The Comparative Pharmacology and Up-Regulation of Rat Neuronal Nicotinic Receptor Subtype Binding Sites Stably Expressed in Transfected Mammalian Cells
We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor α2, α3, or α4 subunits in combination with the β2 or β4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat ne...
Saved in:
Published in | The Journal of pharmacology and experimental therapeutics Vol. 310; no. 1; pp. 98 - 107 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Pharmacology and Experimental Therapeutics
01.07.2004
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor α2,
α3, or α4 subunits in combination with the β2 or β4 subunit to generate six cell lines that express defined subunit combinations
that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated
KXα2β2, KXα2β4, KXα3β2, KXα3β4, KXα4β2, and KXα4β4. The K d values of [ 3 H](±)epibatidine ([ 3 H]EB) binding to membranes from these six cell lines ranged from â¼0.02 to 0.3 nM. The pharmacological profiles of the agonist
binding sites of these putative nAChR subtypes were examined in competition studies in which unlabeled nicotinic ligands,
including 10 agonists and two antagonists, competed against [ 3 H]EB. Most nicotinic ligands examined had higher affinity for the receptor subtypes containing the β2 subunit compared with
those containing the β4 subunit. An excellent correlation ( r > 0.99) of the binding affinities of the 10 agonists was observed between receptors from KXα4β2 cells and from rat forebrain
tissue, in which [ 3 H]EB binding represents predominantly α4β2 nAChRs. More important, the affinities ( K i values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased
after a 5-day exposure to (-)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines
expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation
of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds. |
---|---|
AbstractList | We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor alpha2, alpha3, or alpha4 subunits in combination with the beta2 or beta4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated KXalpha2beta2, KXalpha2beta4, KXalpha3beta2, KXalpha3beta4, KXalpha4beta2, and KXalpha4beta4. The Kd values of [3H](+/-)epibatidine ([3H]EB) binding to membranes from these six cell lines ranged from approximately 0.02 to 0.3 nM. The pharmacological profiles of the agonist binding sites of these putative nAChR subtypes were examined in competition studies in which unlabeled nicotinic ligands, including 10 agonists and two antagonists, competed against [3H]EB. Most nicotinic ligands examined had higher affinity for the receptor subtypes containing the beta2 subunit compared with those containing the beta4 subunit. An excellent correlation (r > 0.99) of the binding affinities of the 10 agonists was observed between receptors from KXalpha4beta2 cells and from rat forebrain tissue, in which [3H]EB binding represents predominantly alpha4beta2 nAChRs. More important, the affinities (Ki values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased after a 5-day exposure to (-)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds. We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor α2, α3, or α4 subunits in combination with the β2 or β4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated KXα2β2, KXα2β4, KXα3β2, KXα3β4, KXα4β2, and KXα4β4. The K d values of [ 3 H](±)epibatidine ([ 3 H]EB) binding to membranes from these six cell lines ranged from â¼0.02 to 0.3 nM. The pharmacological profiles of the agonist binding sites of these putative nAChR subtypes were examined in competition studies in which unlabeled nicotinic ligands, including 10 agonists and two antagonists, competed against [ 3 H]EB. Most nicotinic ligands examined had higher affinity for the receptor subtypes containing the β2 subunit compared with those containing the β4 subunit. An excellent correlation ( r > 0.99) of the binding affinities of the 10 agonists was observed between receptors from KXα4β2 cells and from rat forebrain tissue, in which [ 3 H]EB binding represents predominantly α4β2 nAChRs. More important, the affinities ( K i values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased after a 5-day exposure to (-)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds. We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor alpha2, alpha3, or alpha4 subunits in combination with the beta2 or beta4 subunit to generate six cell lines that express defined subunit combinations that represent potential subtypes of rat neuronal nicotinic acetylcholine receptors (nAChRs). These cell lines were designated KXalpha2beta2, KXalpha2beta4, KXalpha3beta2, KXalpha3beta4, KXalpha4beta2, and KXalpha4beta4. The Kd values of [3H](+/-)epibatidine ([3H]EB) binding to membranes from these six cell lines ranged from approximately 0.02 to 0.3 nM. The pharmacological profiles of the agonist binding sites of these putative nAChR subtypes were examined in competition studies in which unlabeled nicotinic ligands, including 10 agonists and two antagonists, competed against [3H]EB. Most nicotinic ligands examined had higher affinity for the receptor subtypes containing the beta2 subunit compared with those containing the beta4 subunit. An excellent correlation (r > 0.99) of the binding affinities of the 10 agonists was observed between receptors from KXalpha4beta2 cells and from rat forebrain tissue, in which [3H]EB binding represents predominantly alpha4beta2 nAChRs. More important, the affinities (Ki values) for the two tissues were nearly identical. The densities of the binding sites of all six cell lines were increased after a 5-day exposure to (-)-nicotine or the quaternary amine agonist carbachol. These data indicate that these cell lines expressing nAChR subunit combinations should be useful models for investigating pharmacological properties and regulation of the binding sites of potential nAChR subtypes, as well as for studying the properties of nicotinic compounds. |
Author | Yingxian Xiao Kenneth J. Kellar |
Author_xml | – sequence: 1 givenname: Yingxian surname: Xiao fullname: Xiao, Yingxian organization: Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20057-2195, USA – sequence: 2 givenname: Kenneth J surname: Kellar fullname: Kellar, Kenneth J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15016836$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkc2P0zAQxS20iO0unLkhX-CWrj8SNzlCtXxIy4La7tmaOOPWq8QOtgP0L-HfJVVXgtPoaX7zNHrvilz44JGQ15wtORflzeOIeclZuWRKrerVM7LgleAF40xekAVjQhSyUtUluUrpkTFelkq-IJe8YlzVUi3In90B6ToMI0TI7ifS7weIA5jQh_2Rgu_ow1hscD_18zp4GizdQKb3OMXgoaf3zoTsvDN0gwbHHCLdTm0-jkg_ON85v6dblzHRbYa2P9Lb32PElLCjztNdBJ8smjzLrzAM0DvwdI19n16S5xb6hK-e5jV5-Hi7W38u7r59-rJ-f1cYWTe5sC2uGm5Y2a1KBa2sVSOYbCowsjFga9k2Spi6sa0VIKzBjileI7TczlDZyWvy7uw7xvBjwpT14JKZPwCPYUpaKVUJUTUzeHMGTQwpRbR6jG6AeNSc6VMX-tTFLEp97mK-ePNkPbUDdv_4p_Bn4O0ZOLj94ZeLqMf_wtfyZKybWv4FNb-Xug |
CitedBy_id | crossref_primary_10_1124_jpet_107_121228 crossref_primary_10_1021_jm1006148 crossref_primary_10_1016_j_ejmech_2014_04_044 crossref_primary_10_1007_s11064_015_1705_z crossref_primary_10_1016_j_ejphar_2014_06_005 crossref_primary_10_1124_mol_105_012369 crossref_primary_10_1016_j_bmcl_2005_06_039 crossref_primary_10_1124_mol_115_098285 crossref_primary_10_1186_s12576_024_00913_8 crossref_primary_10_1369_00221554231203038 crossref_primary_10_1002_jlcr_2923 crossref_primary_10_1016_j_aca_2005_09_020 crossref_primary_10_1002_syn_20480 crossref_primary_10_1038_npp_2013_105 crossref_primary_10_1002_cmdc_200700073 crossref_primary_10_1002_cne_24320 crossref_primary_10_1038_s41598_018_24166_9 crossref_primary_10_1016_j_ijbiomac_2014_06_058 crossref_primary_10_1124_mol_106_027458 crossref_primary_10_1124_jpet_118_248070 crossref_primary_10_1002_syn_20776 crossref_primary_10_3389_fnana_2018_00001 crossref_primary_10_1038_npp_2011_322 crossref_primary_10_1007_s43440_022_00375_y crossref_primary_10_1016_j_bbamem_2014_11_003 crossref_primary_10_1186_2050_6511_14_2 crossref_primary_10_1016_j_neuropharm_2015_02_005 crossref_primary_10_1074_jbc_M111_289546 crossref_primary_10_1074_jbc_M110_105346 crossref_primary_10_1124_jpet_112_192542 crossref_primary_10_1523_JNEUROSCI_1795_17_2017 crossref_primary_10_3390_molecules26123603 crossref_primary_10_3987_COM_08_S_D_19 crossref_primary_10_1124_jpet_110_178236 crossref_primary_10_1111_j_1742_4658_2007_05935_x crossref_primary_10_1074_jbc_M110_171645 crossref_primary_10_1124_jpet_112_198085 crossref_primary_10_1016_j_bmc_2009_05_021 crossref_primary_10_1016_j_neuropharm_2013_09_023 crossref_primary_10_1016_j_jphysparis_2005_12_012 crossref_primary_10_1021_jm4000374 crossref_primary_10_1016_j_nlm_2012_04_003 crossref_primary_10_1124_mol_106_025338 crossref_primary_10_1021_np900727e crossref_primary_10_1097_FJC_0000000000000221 crossref_primary_10_1021_acschemneuro_2c00610 crossref_primary_10_1371_journal_pone_0048665 crossref_primary_10_1021_jm500183r crossref_primary_10_1007_s12192_023_01395_0 crossref_primary_10_1111_j_1471_4159_2007_05011_x crossref_primary_10_1124_mol_105_012419 crossref_primary_10_1111_j_1471_4159_2009_06299_x crossref_primary_10_1016_j_neuropharm_2016_07_020 crossref_primary_10_1016_j_bcp_2007_07_039 crossref_primary_10_1016_j_bmcl_2014_04_036 crossref_primary_10_1093_ntr_nty134 crossref_primary_10_1248_yakushi_130_377 crossref_primary_10_1111_j_1471_4159_2011_07408_x crossref_primary_10_1212_WNL_0000000000001471 crossref_primary_10_1124_mol_105_014902 crossref_primary_10_1016_j_pnpbp_2010_07_037 crossref_primary_10_1523_JNEUROSCI_2112_05_2005 crossref_primary_10_1124_mol_116_106880 crossref_primary_10_1113_JP274467 crossref_primary_10_1096_fj_10_179853 crossref_primary_10_1007_s00213_012_2808_8 crossref_primary_10_1021_jm900225j crossref_primary_10_1124_mol_115_099978 crossref_primary_10_1038_mp_2009_59 crossref_primary_10_1002_med_20036 crossref_primary_10_1101_cshperspect_a039776 crossref_primary_10_2967_jnumed_111_092338 crossref_primary_10_1186_2046_1682_4_19 crossref_primary_10_1007_s10571_007_9149_x crossref_primary_10_1016_j_ejmech_2015_03_025 crossref_primary_10_1016_j_lfs_2012_08_004 crossref_primary_10_1371_journal_pone_0143319 crossref_primary_10_1124_jpet_113_211235 crossref_primary_10_1016_j_bbamem_2009_06_012 crossref_primary_10_1016_j_bcp_2009_05_024 crossref_primary_10_1002_syn_22116 crossref_primary_10_4049_jimmunol_179_5_2889 crossref_primary_10_1021_jm401543h crossref_primary_10_1111_j_1471_4159_2008_05282_x crossref_primary_10_1111_j_1471_4159_2010_06967_x crossref_primary_10_1016_j_bcp_2015_07_030 crossref_primary_10_1074_jbc_M806136200 crossref_primary_10_1002_syn_20693 crossref_primary_10_1002_bip_22413 crossref_primary_10_1007_s00213_018_4883_y crossref_primary_10_1038_mp_2013_104 crossref_primary_10_1002_psc_2467 crossref_primary_10_1111_j_1471_4159_2010_06819_x crossref_primary_10_1124_mol_106_027326 crossref_primary_10_1016_j_neulet_2023_137279 crossref_primary_10_1016_j_nucmedbio_2014_12_008 crossref_primary_10_1124_mol_104_002345 crossref_primary_10_1016_j_bcp_2013_06_023 crossref_primary_10_1124_mol_105_021782 crossref_primary_10_1021_acs_jnatprod_8b00062 crossref_primary_10_1016_j_neuropharm_2007_05_026 crossref_primary_10_1111_j_1601_183X_2008_00444_x crossref_primary_10_1021_jm4008455 crossref_primary_10_1111_j_1471_4159_2007_05009_x crossref_primary_10_1016_j_neuropharm_2007_05_021 crossref_primary_10_1074_jbc_M109_019083 crossref_primary_10_1208_aapsj070486 crossref_primary_10_1038_aps_2009_68 crossref_primary_10_1016_j_bmcl_2012_02_052 crossref_primary_10_1124_jpet_110_173773 crossref_primary_10_1074_jbc_M110_108803 crossref_primary_10_1124_mol_106_027318 crossref_primary_10_1038_aps_2009_69 crossref_primary_10_1021_jm401184f crossref_primary_10_1016_j_neuropharm_2016_06_032 crossref_primary_10_1074_jbc_M707330200 crossref_primary_10_1021_jm800323d crossref_primary_10_1124_mol_118_114769 crossref_primary_10_1371_journal_pone_0254247 crossref_primary_10_2967_jnumed_108_061374 crossref_primary_10_1007_s00259_007_0701_1 crossref_primary_10_1152_physrev_00015_2008 crossref_primary_10_1007_s00213_016_4238_5 crossref_primary_10_1016_j_jneuroim_2005_05_007 |
Cites_doi | 10.1016/0006-2952(73)90196-2 10.1124/mol.51.5.776 10.1523/JNEUROSCI.18-13-04946.1998 10.1016/0006-8993(93)91104-Z 10.1016/0169-328X(94)00189-L 10.1111/j.1469-7793.1997.299bb.x 10.1124/mol.55.6.970 10.1111/j.1471-4159.1988.tb10600.x 10.1016/0014-5793(90)81231-C 10.1523/JNEUROSCI.12-07-02765.1992 10.1074/jbc.270.9.4424 10.1126/science.6828889 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X 10.1124/mol.54.5.779 10.1074/jbc.273.44.28721 10.1124/mol.64.6.1283 10.1111/1523-1747.ep12325606 10.1073/pnas.84.21.7763 10.1016/S0079-6123(08)62094-4 10.1016/S1054-3589(08)60072-1 10.1046/j.1471-4159.1996.67051953.x 10.1016/S0079-6123(08)62480-2 10.1152/jn.1995.74.3.1212 10.1124/mol.54.6.1132 10.1016/S0028-3908(98)00221-4 10.1046/j.1471-4159.1997.69052216.x 10.1124/mol.54.2.322 10.1046/j.1471-4159.2003.01774.x 10.1124/mol.64.4.974 10.1073/pnas.84.2.595 10.1016/0896-6273(89)90207-9 10.1046/j.1471-4159.2002.00951.x 10.1113/jphysiol.2001.013456 10.1073/pnas.0630641100 10.1124/mol.64.4.865 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1124/jpet.104.066787 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0103 |
EndPage | 107 |
ExternalDocumentID | 10_1124_jpet_104_066787 15016836 310_1_98 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article Comparative Study |
GrantInformation_xml | – fundername: NIDA NIH HHS grantid: DA06486 – fundername: NIDA NIH HHS grantid: DA12976 |
GroupedDBID | - 08R 0R 2WC 3O- 4.4 53G 55 5GY 5RE 8RP AALRV ABFLS ABIVO ABOCM ABSGY ABZEH ACDCL ACGFS ACNCT ADACO ADBIT ADCOW ADKFC AENEX AETEA AFFNX AIKQT ALMA_UNASSIGNED_HOLDINGS CS3 DIK DL DU5 E3Z EBS EJD F5P FH7 GJ GX1 H13 HZ INIJC KQ8 L7B LSO O0- O9- OHT OK1 P2P R.V R0Z RHF RHI RPT W2D WH7 WOQ X X7M ZGI ZXP --- -~X .55 .GJ 0R~ 18M 5VS 8WZ A6W AAJMC AAYOK ABCQX ABJNI ABSQV ACGFO ADBBV ADIYS AERNN AFHIN AFOSN AGFXO AI. BAWUL BTFSW CGR CUY CVF ECM EIF F9R HZ~ MJL MVM NPM TR2 UQL VH1 W8F YBU YHG YQT AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c389t-fbe791c04d746ab386920395ac39caf83b962c89fbf2a2fced0618eab1f95a4d3 |
ISSN | 0022-3565 |
IngestDate | Fri Oct 25 05:31:16 EDT 2024 Thu Sep 26 17:48:18 EDT 2024 Sat Sep 28 07:41:56 EDT 2024 Tue Jan 05 21:16:48 EST 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c389t-fbe791c04d746ab386920395ac39caf83b962c89fbf2a2fced0618eab1f95a4d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 15016836 |
PQID | 66652259 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_66652259 crossref_primary_10_1124_jpet_104_066787 pubmed_primary_15016836 highwire_pharmacology_310_1_98 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 2004-07-01 |
PublicationDateYYYYMMDD | 2004-07-01 |
PublicationDate_xml | – month: 07 year: 2004 text: 2004-07-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of pharmacology and experimental therapeutics |
PublicationTitleAlternate | J Pharmacol Exp Ther |
PublicationYear | 2004 |
Publisher | American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: American Society for Pharmacology and Experimental Therapeutics |
References | 2019081412044966000_310.1.98.4 2019081412044966000_310.1.98.5 2019081412044966000_310.1.98.7 2019081412044966000_310.1.98.8 2019081412044966000_310.1.98.9 2019081412044966000_310.1.98.32 2019081412044966000_310.1.98.30 2019081412044966000_310.1.98.2 2019081412044966000_310.1.98.34 2019081412044966000_310.1.98.3 2019081412044966000_310.1.98.39 (2019081412044966000_310.1.98.46) 1995; 28 2019081412044966000_310.1.98.38 2019081412044966000_310.1.98.37 (2019081412044966000_310.1.98.29) 1998; 285 (2019081412044966000_310.1.98.22) 1989; 79 (2019081412044966000_310.1.98.48) 1998; 18 2019081412044966000_310.1.98.43 (2019081412044966000_310.1.98.17) 1996; 276 2019081412044966000_310.1.98.42 (2019081412044966000_310.1.98.19) 1996; 67 2019081412044966000_310.1.98.41 2019081412044966000_310.1.98.47 (2019081412044966000_310.1.98.15) 1997; 69 2019081412044966000_310.1.98.44 (2019081412044966000_310.1.98.28) 1992; 12 2019081412044966000_310.1.98.49 (2019081412044966000_310.1.98.16) 1992; 41 (2019081412044966000_310.1.98.45) 1991; 40 (2019081412044966000_310.1.98.31) 2001; 60 2019081412044966000_310.1.98.10 (2019081412044966000_310.1.98.36) 1999; 289 2019081412044966000_310.1.98.14 2019081412044966000_310.1.98.13 (2019081412044966000_310.1.98.40) 1998; 284 2019081412044966000_310.1.98.12 2019081412044966000_310.1.98.11 2019081412044966000_310.1.98.18 (2019081412044966000_310.1.98.1) 1997; 280 (2019081412044966000_310.1.98.35) 1994; 46 (2019081412044966000_310.1.98.20) 1999; 25 (2019081412044966000_310.1.98.25) 1998; 287 (2019081412044966000_310.1.98.26) 1995; 74 (2019081412044966000_310.1.98.33) 1996; 278 (2019081412044966000_310.1.98.27) 1983; 226 2019081412044966000_310.1.98.21 2019081412044966000_310.1.98.24 2019081412044966000_310.1.98.23 (2019081412044966000_310.1.98.6) 1997; 280 |
References_xml | – volume: 25 start-page: 980 year: 1999 ident: 2019081412044966000_310.1.98.20 publication-title: Soc Neurosci – ident: 2019081412044966000_310.1.98.7 doi: 10.1016/0006-2952(73)90196-2 – ident: 2019081412044966000_310.1.98.34 doi: 10.1124/mol.51.5.776 – volume: 18 start-page: 4946 year: 1998 ident: 2019081412044966000_310.1.98.48 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.18-13-04946.1998 – ident: 2019081412044966000_310.1.98.38 doi: 10.1016/0006-8993(93)91104-Z – volume: 28 start-page: 101 year: 1995 ident: 2019081412044966000_310.1.98.46 publication-title: Brain Res Mol Brain Res doi: 10.1016/0169-328X(94)00189-L – volume: 289 start-page: 1545 year: 1999 ident: 2019081412044966000_310.1.98.36 publication-title: J Pharmacol Exp Ther – ident: 2019081412044966000_310.1.98.23 doi: 10.1111/j.1469-7793.1997.299bb.x – ident: 2019081412044966000_310.1.98.49 doi: 10.1124/mol.55.6.970 – ident: 2019081412044966000_310.1.98.3 doi: 10.1111/j.1471-4159.1988.tb10600.x – ident: 2019081412044966000_310.1.98.43 doi: 10.1016/0014-5793(90)81231-C – volume: 12 start-page: 2765 year: 1992 ident: 2019081412044966000_310.1.98.28 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.12-07-02765.1992 – volume: 60 start-page: 568 year: 2001 ident: 2019081412044966000_310.1.98.31 publication-title: Mol Pharmacol – ident: 2019081412044966000_310.1.98.9 doi: 10.1074/jbc.270.9.4424 – ident: 2019081412044966000_310.1.98.39 doi: 10.1126/science.6828889 – volume: 46 start-page: 523 year: 1994 ident: 2019081412044966000_310.1.98.35 publication-title: Mol Pharmacol – ident: 2019081412044966000_310.1.98.5 doi: 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X – ident: 2019081412044966000_310.1.98.30 doi: 10.1124/mol.54.5.779 – ident: 2019081412044966000_310.1.98.41 doi: 10.1074/jbc.273.44.28721 – ident: 2019081412044966000_310.1.98.13 doi: 10.1124/mol.64.6.1283 – ident: 2019081412044966000_310.1.98.18 doi: 10.1111/1523-1747.ep12325606 – ident: 2019081412044966000_310.1.98.4 doi: 10.1073/pnas.84.21.7763 – volume: 276 start-page: 289 year: 1996 ident: 2019081412044966000_310.1.98.17 publication-title: J Pharmacol Exp Ther – ident: 2019081412044966000_310.1.98.24 doi: 10.1016/S0079-6123(08)62094-4 – ident: 2019081412044966000_310.1.98.8 doi: 10.1016/S1054-3589(08)60072-1 – volume: 67 start-page: 1953 year: 1996 ident: 2019081412044966000_310.1.98.19 publication-title: J Neurochem doi: 10.1046/j.1471-4159.1996.67051953.x – volume: 284 start-page: 777 year: 1998 ident: 2019081412044966000_310.1.98.40 publication-title: J Pharmacol Exp Ther – volume: 79 start-page: 209 year: 1989 ident: 2019081412044966000_310.1.98.22 publication-title: Prog Brain Res doi: 10.1016/S0079-6123(08)62480-2 – volume: 74 start-page: 1212 year: 1995 ident: 2019081412044966000_310.1.98.26 publication-title: J Neurophysiol doi: 10.1152/jn.1995.74.3.1212 – ident: 2019081412044966000_310.1.98.32 doi: 10.1124/mol.54.6.1132 – volume: 287 start-page: 435 year: 1998 ident: 2019081412044966000_310.1.98.25 publication-title: J Pharmacol Exp Ther – ident: 2019081412044966000_310.1.98.10 doi: 10.1016/S0028-3908(98)00221-4 – volume: 278 start-page: 361 year: 1996 ident: 2019081412044966000_310.1.98.33 publication-title: J Pharmacol Exp Ther – volume: 41 start-page: 31 year: 1992 ident: 2019081412044966000_310.1.98.16 publication-title: Mol Pharmacol – volume: 69 start-page: 2216 year: 1997 ident: 2019081412044966000_310.1.98.15 publication-title: J Neurochem doi: 10.1046/j.1471-4159.1997.69052216.x – volume: 280 start-page: 346 year: 1997 ident: 2019081412044966000_310.1.98.6 publication-title: J Pharmacol Exp Ther – ident: 2019081412044966000_310.1.98.47 doi: 10.1124/mol.54.2.322 – ident: 2019081412044966000_310.1.98.11 doi: 10.1046/j.1471-4159.2003.01774.x – volume: 40 start-page: 463 year: 1991 ident: 2019081412044966000_310.1.98.45 publication-title: Mol Pharmacol – ident: 2019081412044966000_310.1.98.2 doi: 10.1124/mol.64.4.974 – ident: 2019081412044966000_310.1.98.44 doi: 10.1073/pnas.84.2.595 – ident: 2019081412044966000_310.1.98.12 doi: 10.1016/0896-6273(89)90207-9 – volume: 285 start-page: 377 year: 1998 ident: 2019081412044966000_310.1.98.29 publication-title: J Pharmacol Exp Ther – ident: 2019081412044966000_310.1.98.37 doi: 10.1046/j.1471-4159.2002.00951.x – volume: 226 start-page: 817 year: 1983 ident: 2019081412044966000_310.1.98.27 publication-title: J Pharmacol Exp Ther – ident: 2019081412044966000_310.1.98.42 doi: 10.1113/jphysiol.2001.013456 – ident: 2019081412044966000_310.1.98.14 doi: 10.1073/pnas.0630641100 – ident: 2019081412044966000_310.1.98.21 doi: 10.1124/mol.64.4.865 – volume: 280 start-page: 1117 year: 1997 ident: 2019081412044966000_310.1.98.1 publication-title: J Pharmacol Exp Ther |
SSID | ssj0014463 |
Score | 2.2282128 |
Snippet | We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor α2,
α3, or α4 subunits in combination... We stably transfected human embryonic kidney cells (HEK 293 cells) with genes encoding rat neuronal nicotinic receptor alpha2, alpha3, or alpha4 subunits in... |
SourceID | proquest crossref pubmed highwire |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 98 |
SubjectTerms | Animals Binding Sites Bridged Bicyclo Compounds, Heterocyclic - pharmacology Carbachol - pharmacology Cell Line Cholinergic Agonists - pharmacology Gene Expression - drug effects Humans Neurons - drug effects Neurons - metabolism Nicotine - pharmacology Nicotinic Agonists - pharmacology Pyridines - pharmacology Rats Receptors, Nicotinic - drug effects Receptors, Nicotinic - metabolism Transfection Tritium Up-Regulation - drug effects |
Title | The Comparative Pharmacology and Up-Regulation of Rat Neuronal Nicotinic Receptor Subtype Binding Sites Stably Expressed in Transfected Mammalian Cells |
URI | http://jpet.aspetjournals.org/content/310/1/98.abstract https://www.ncbi.nlm.nih.gov/pubmed/15016836 https://search.proquest.com/docview/66652259 |
Volume | 310 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFcadchh_QhNSlpHGS2o9QDU2bQDBaqTxFdmKLSr1pSyXGH-HfIs6xk9Tphri8RG1SOW6-L8ffsc85JuTlkHElTJ4EYaiiABRxHshEDoJhUXClQqU1x0Th9x_S40l8Mk2mnc5PL2ppU6p-_v3avJL_QRXOAa6YJfsPyDaNwgn4DPjCERCG419jPPLKd3_c1qF2ZZUm6-DMbTZf6cIzWfZsPQ4UociCEhMjUTzqNXjfaEfspOzbmct2-TzDeVlQpGp-iWWRbalxLNfkqqJjLIjGQI3Fws2XjPR8fuEL3m3qmRW9690etnYY8JLBGqn_BbrxDZuezuSqNTyUX3sn_d4phm-dtyYv4ibQtfTyBdCQeSGqV57Vkd-T8W5P_KQEt-1EX1e2PMKZkpD5xp5VQbQ-q53pdpthXx1RohhHFHBhcDm8jzHBTiF4_FovLMFAWw9Szq6p7L0z4jZxkAxdsEzwG-RmBIYSLfTpp-0qGLjqrKl2D3-uKk0FXXq90yG7u5S7e1tg1UWvf-9AWSE1vkNuV2Sgbxyd75KOXt4jBxUcl4fUf_SH9ID6QN0nP-Ay9TjfukwBR9riPF0ZCpynNedpw3lac55WnKcV56nlPHWcpw3n6WxJPc7ThvPUcv4Bmbw7Go-Og2pzkSAHjV4GRumhGORhXAzjVCrGUxGFTCQyZyKXhjMl0ijnwigTycjkugDly7VUAwM_igv2kOwtV0v9mFApBiZkMkwVl-DNpzwXOgEhbGLJRcRNl7yqEcnWroZMZn3vKM4QR_gSZw7HLtmvEcv8NzKrmdIlL2ocMxgIcHVPLvVqc5GlaQq-VCK65JGDd3uvihlP_tT4U3Jr-5I-I3vl-UY_B81dqn1LzF8Or-MJ |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Comparative+Pharmacology+and+Up-Regulation+of+Rat+Neuronal+Nicotinic+Receptor+Subtype+Binding+Sites+Stably+Expressed+in+Transfected+Mammalian+Cells&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Yingxian+Xiao&rft.au=Kenneth+J.+Kellar&rft.date=2004-07-01&rft.pub=American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0022-3565&rft.eissn=1521-0103&rft.volume=310&rft.issue=1&rft.spage=98&rft_id=info:doi/10.1124%2Fjpet.104.066787&rft_id=info%3Apmid%2F15016836&rft.externalDBID=n%2Fa&rft.externalDocID=310_1_98 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3565&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3565&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3565&client=summon |